GlassScriptPhysician profile
Douglas Thompson
NPI 1083145668
$1,521.29
in general payments reported to CMS, 2019-2025
13 companies · $654 in 2025
The $654 reported for 2025 was more than what 86% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.08 · 2022: $13.85 · 2023: $391 · 2024: $436 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.51 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $217.22 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $126.66 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $71.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.08 | 2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $55.08 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $30.53 | 2019-2025 | Shingrix |
| Axsome Therapeutics, INC. | $30.09 | 2025 | Auvelity |
| Tolmar, INC. | $16.40 | 2025 | Jatenzo |
| Bioventus LLC | $15.38 | 2025 | Durolane |
| Xeris Pharmaceuticals, INC. | $15.24 | 2025 | Recorlev |
| Kaleo, INC. | $14.27 | 2023 | Auvi-Q |
| Kowa Pharmaceuticals America, INC. | $13.65 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.